Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Discov. 2012 Aug;2(8):673-5. doi: 10.1158/2159-8290.CD-12-0311.

Turn off the IDO: will clinical trials be successful?

Author information

1
Vanderbilt University, Nashville, Tennessee, USA.

Abstract

Indoleamine 2,3-dioxygenase (IDO) is overexpressed in many human cancers and is believed to play a role in tumor immune evasion, but a requirement for IDO in tumor progression has not been formally shown. The study by Smith and colleagues in this issue of Cancer Discovery provides genetic evidence for the importance of IDO in tumorigenesis, which supports the use of IDO inhibitors in clinical trials in humans.

PMID:
22886661
DOI:
10.1158/2159-8290.CD-12-0311
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center